Electrical pulses that kill abnormal cells while sparing the nerve that lets you breathe
In Chennai, a hospital system has quietly moved the boundary of what cardiac care looks like in Tamil Nadu. Kauvery Hospital has introduced pulsed field ablation — a technology that treats dangerous heart rhythms not with heat or cold, but with precisely calibrated electrical pulses that spare the surrounding tissue — marking the first deployment of both leading PFA platforms in the state. The arrival of this technology, supported by visiting specialists from the United States and paired with an affordable early-screening programme, reflects a broader truth: that the distance between patients and the frontier of medicine is, slowly, closing.
- Atrial fibrillation affects millions worldwide, yet many patients in Tamil Nadu have had no access to the safest, most precise treatments available — until now.
- Conventional ablation methods carry real risks of collateral damage to the oesophagus, phrenic nerve, and blood vessels, creating a tension between treating the arrhythmia and protecting the patient.
- Kauvery simultaneously deployed two distinct PFA systems across two locations, with US electrophysiology specialists present for the first procedures to ensure the programme launched with genuine expertise.
- The Varipulse™ system at Vadapalani integrates real-time 3D cardiac mapping, giving clinicians a live picture of the heart's electrical landscape — a first for the state.
- A new Heart Rhythm Package aims to intercept the problem earlier, reaching people with palpitations or unexplained fatigue before atrial fibrillation progresses to stroke or heart failure.
Kauvery Hospital has introduced pulsed field ablation to Tamil Nadu — a treatment approach that uses controlled electrical pulses to eliminate abnormal heart tissue responsible for dangerous arrhythmias, most notably atrial fibrillation. Unlike older ablation methods that rely on extreme heat or cold, PFA works through electroporation: electrical pulses open tiny pores in the membranes of targeted cells, causing them to die while leaving the oesophagus, phrenic nerve, and nearby vessels largely unharmed. The result is a more precise procedure with a lower risk of collateral damage and the potential for faster recovery.
The programme spans two hospital locations. Medtronic's PulseSelect™ system is now operational at the Alwarpet facility, while Biosense Webster's Varipulse™ — integrated with a three-dimensional cardiac mapping platform for real-time visualization of the heart's electrical activity — has been installed at Vadapalani. Both systems are arriving in Tamil Nadu for the first time, and the 3D-integrated PFA platform represents a state-level first. To anchor the launch in clinical confidence, electrophysiology specialists from the United States joined Kauvery's cardiac team for the initial procedures.
Alongside the technology, the hospital introduced an affordable Heart Rhythm Package designed for early detection. It targets people experiencing palpitations, breathlessness, dizziness, or unexplained fatigue — symptoms that often go uninvestigated until a more serious event occurs. The hospital framed early diagnosis as a meaningful intervention in itself, given that untreated atrial fibrillation can lead to stroke and heart failure. For patients across Chennai and the surrounding region, the simultaneous availability of both major PFA platforms within a single hospital system represents a shift that was simply not possible just weeks ago.
Kauvery Hospital has brought a new class of heart treatment to Tamil Nadu. The hospital system has launched its first Pulsed Field Ablation programme—a technology that uses controlled electrical pulses instead of heat or cold to treat dangerous heart rhythms, particularly atrial fibrillation, the most common arrhythmia affecting millions worldwide.
The programme spans two locations. At the Alwarpet facility, clinicians now have access to Medtronic's PulseSelect™ system. At Vadapalani, the hospital installed Biosense Webster's Varipulse™, integrated with an advanced three-dimensional cardiac mapping platform that allows doctors to visualize the heart's electrical activity in real time before and during treatment. This marks the first time both systems have arrived in the state, and the first time a 3D mapping-integrated PFA platform has been deployed here.
What makes pulsed field ablation different from older methods is its precision. Conventional ablation destroys tissue using extreme heat or cold—effective, but blunt. PFA works through electroporation, a process in which electrical pulses create tiny openings in the membranes of abnormal heart cells, causing them to die while leaving surrounding structures largely untouched. The oesophagus, the phrenic nerve that controls breathing, and nearby blood vessels face far less risk of collateral damage. For patients, this means a safer procedure with potentially faster recovery and fewer complications.
To ensure the programme launched with expertise, leading electrophysiology specialists from the United States traveled to Chennai and worked alongside Kauvery's cardiac team during the first procedures. The hospital's cardiologist Dr. N.S. Sivakadaksham attended the launch event as chief guest, endorsing the technology's potential to reshape outcomes for patients living with rhythm disorders.
Beyond the technology itself, Kauvery introduced what it calls the Heart Rhythm Package—an affordable screening and evaluation programme designed to catch problems early. The package targets people experiencing palpitations, breathlessness, dizziness, unexplained fatigue, or rapid heartbeat. Early detection matters. A patient who learns they have atrial fibrillation and begins treatment promptly can avoid stroke, heart failure, and the cascade of complications that come with untreated arrhythmia. The hospital framed the package as a way to improve long-term outcomes and quality of life, acknowledging that access to diagnosis has historically been a barrier for many.
The launch signals a shift in how Tamil Nadu's cardiac care landscape is evolving. Pulsed field ablation represents the frontier of electrophysiology—newer than radiofrequency or cryoablation, with a growing body of evidence supporting its safety and efficacy. For patients in Chennai and surrounding regions who need rhythm management, the arrival of both major PFA platforms in a single hospital system means choice, expertise, and access to technology that was unavailable in the state just weeks ago.
Citas Notables
The technology targets affected cells while minimising damage to surrounding structures, making it a safer and more efficient non-thermal treatment option— Kauvery Hospital officials
The package is designed to encourage early detection and timely treatment, helping improve long-term patient outcomes and quality of life— Hospital officials
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that both systems arrived at the same hospital, rather than just one?
Competition and redundancy. If one system has downtime or a patient isn't a good candidate for one approach, the team has another option. It also means the hospital can compare outcomes, learn which works better for which patients, and build real expertise rather than just owning a machine.
The electrical pulse approach—is that actually safer, or just marketed that way?
The mechanism is genuinely different. Heat and cold spread through tissue. Electrical pulses are more targeted at the cellular level. But "safer" depends on the operator's skill and the patient's anatomy. What matters is that the risk profile is different enough that some patients who couldn't tolerate older methods might now be candidates.
Why did American specialists need to come train the team?
PFA is still relatively new globally. The learning curve is steep. Having someone who's done hundreds of these procedures walk through the first few cases reduces errors and builds confidence faster than learning from textbooks or videos.
The Heart Rhythm Package—is that just a marketing name, or something real?
It's real in that it's a structured pathway: screening, diagnosis, treatment planning. But it's also marketing. The hospital is signaling that they're not just buying expensive technology—they're thinking about access and early detection. That matters for a patient who might otherwise ignore palpitations until they have a stroke.
What happens to patients who can't afford the package?
The source doesn't say. That's the question worth asking.